The higher female frequency is expected considering that ovarian cancer represents the first therapeutic indication olaparib was approved for, followed by HER2-negative metastatic breast cancer and, only in 2022, its indication was extended for the treatment of metastatic castration-resistant prostate cancer too (Food and Drug Administration, 2024a; Food and Drug Administration, 2024b; Food and Drug Administration, 2024c; Rydberg et al., 2018). Here, ERBB2 is linked to prostate carcinoma.